A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy Read more about A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy
Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma Read more about Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma
Minimizing Toxicity in HLA-identical Related Donor Transplantation for Children With Sickle Cell Disease Read more about Minimizing Toxicity in HLA-identical Related Donor Transplantation for Children With Sickle Cell Disease
Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy Read more about Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy
Sleep for Stroke Management and Recovery Trial Read more about Sleep for Stroke Management and Recovery Trial
5-Cog Battery for Detecting Cognitive Impairment and Dementia Read more about 5-Cog Battery for Detecting Cognitive Impairment and Dementia
Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA) Read more about Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)
Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation Read more about Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS) Read more about CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS)